152 related articles for article (PubMed ID: 17009990)
1. Immunohistochemical characterization of cancer antigen in uterine cancers.
Nur S; Chuang L; Ramaswamy G
Int J Gynecol Cancer; 2006; 16(5):1903-10. PubMed ID: 17009990
[TBL] [Abstract][Full Text] [Related]
2. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylation-induced expression of S100A4 in endometrial carcinoma.
Xie R; Loose DS; Shipley GL; Xie S; Bassett RL; Broaddus RR
Mod Pathol; 2007 Oct; 20(10):1045-54. PubMed ID: 17673926
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
[TBL] [Abstract][Full Text] [Related]
5. Tenascin expression in normal, hyperplastic, and neoplastic endometrium.
Sedele M; Karaveli S; Peştereli HE; Simşek T; Elpek G; Uner M; Sargin CF
Int J Gynecol Pathol; 2002 Apr; 21(2):161-6. PubMed ID: 11917226
[TBL] [Abstract][Full Text] [Related]
6. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms.
McCluggage WG; Sumathi VP; Maxwell P
Histopathology; 2001 Sep; 39(3):273-8. PubMed ID: 11532038
[TBL] [Abstract][Full Text] [Related]
7. Expression pattern of PAX2 in hyperplastic and malignant endometrium.
Kahraman K; Kiremitci S; Taskin S; Kankaya D; Sertcelik A; Ortac F
Arch Gynecol Obstet; 2012 Jul; 286(1):173-8. PubMed ID: 22274645
[TBL] [Abstract][Full Text] [Related]
8. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
9. Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer.
Woo MM; Alkushi A; Verhage HG; Magliocco AM; Leung PC; Gilks CB; Auersperg N
Clin Cancer Res; 2004 Dec; 10(23):7958-64. PubMed ID: 15585630
[TBL] [Abstract][Full Text] [Related]
10. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
11. Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma.
Shroyer KR; Stephens JK; Silverberg SG; Markham N; Shroyer AL; Wilson ML; Enomoto T
Int J Gynecol Pathol; 1997 Jul; 16(3):225-32. PubMed ID: 9421087
[TBL] [Abstract][Full Text] [Related]
12. Expression of nm23 in normal, hyperplastic and neoplastic endometrial tissues.
Brustmann H; Naudé S
Pathol Res Pract; 1999; 195(12):829-34. PubMed ID: 10631718
[TBL] [Abstract][Full Text] [Related]
13. Significance of p53 expression in background endometrium in endometrial carcinoma.
Nguyen TT; Hachisuga T; Urabe R; Kurita T; Kagami S; Kawagoe T; Shimajiri S; Nabeshima K
Virchows Arch; 2015 Jun; 466(6):695-702. PubMed ID: 25788166
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of the tumour marker CA-125 in normal, hyperplastic and malignant endometrial tissue.
Mylonas I; Makovitzky J; Richter DU; Jeschke U; Briese V; Friese K
Anticancer Res; 2003; 23(2A):1075-80. PubMed ID: 12820350
[TBL] [Abstract][Full Text] [Related]
15. Staining characterization by immunohistochemistry of tumor cancer antigen in patients with endometrial cancer.
Metindir J; Dilek GB; Pak I
Eur J Gynaecol Oncol; 2008; 29(5):489-92. PubMed ID: 19051819
[TBL] [Abstract][Full Text] [Related]
16. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
[TBL] [Abstract][Full Text] [Related]
17. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium.
Stewart CJ; Crook ML; Lacey J; Louwen K
Int J Gynecol Pathol; 2011 Sep; 30(5):484-91. PubMed ID: 21804393
[TBL] [Abstract][Full Text] [Related]
19. Expression of fos and jun proto-oncogenes in benign versus malignant human uterine tissue.
Nephew KP; Choi CM; Polek TC; McBride R; Bigsby RM; Khan SA; Husseinzadeh N
Gynecol Oncol; 2000 Mar; 76(3):388-96. PubMed ID: 10684716
[TBL] [Abstract][Full Text] [Related]
20. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium.
Afify AM; Craig S; Paulino AF; Stern R
Ann Diagn Pathol; 2005 Dec; 9(6):312-8. PubMed ID: 16308159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
